TITLE

Ambitious plans to roll out ARVs

PUB. DATE
March 2004
SOURCE
HIV Australia;Mar-May2004, Vol. 3 Issue 3, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the plan to launch antiviral treatment programs at several pilot centres for HIV-positive people across Zimbabwe in 2004. Support of the World Health Organization for the program; Cost of a triple generic drug treatment; Reasons for choosing the pilot sites for the program.
ACCESSION #
15003614

 

Related Articles

  • Patient Adherence To HAART Regimens: Challenges For Physician Assistants And Health Care Providers. Day, Marvin // Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p42 

    Patients often adhere incompletely and inadequately to highly active antiretroviral therapy (HAART) regimens used in the treatment of HIV infection. This permits the emergence of HIV variants that are resistant to current treatment. The physician assistant often assumes the responsibility for...

  • Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States. Brogan, Anita J.; Mrus, Joseph; Hill, Andrew; Sawyer, Anthony W.; Smets, Erik // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p133 

    Purpose: A comprehensive study comparing the costs and efficacies of darunavir/ritonavir 800/100 mg qd and the other ritonavir-boosted (/r) protease inhibitors (PIs) recommended for treatment-naïve individuals with HIV-1 infection would help health care decision makers identify the value of...

  • Antiretroviral access increased but still room for improvement.  // PharmacoEconomics & Outcomes News;4/8/2006, Issue 500, p26 

    According to the latest report issued by the WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS), the number of patients with HIV infections in low and middle income countries who are receiving antiretroviral (ART) treatments has increased from 400 000 in December 2003 to 1.3 million...

  • WHO's use of generic antiretrovirals needs support.  // PharmacoEconomics & Outcomes News;3/12/2005, Issue 473, p2 

    Presents information on a program implemented by the World Health Organization to increase access to antiretrovirals for HIV-infected individuals in developing countries. Efforts to prove the bioequivalence of generic and brand-name antiretrovirals; Criticism of various international agencies...

  • Robust treatment programs key to HIV epidemic.  // Nation's Health;Aug2004, Vol. 34 Issue 6, p17 

    This article presents the World Health Report 2004--Changing History which was released by the World Health Organization in May. The World Health Organization, United Nations Joint Program on AIDS and several partners are implementing a comprehensive HIV/AIDS strategy that links prevention,...

  • Use of WHO clinical stage for assessing patient eligibility to antiretroviral therapy in a routine health service setting in Jinja, Uganda. Jaffar, Shabbar; Birungi, Josephine; Grosskurth, Heiner; Amuron, Barbara; Namara, Geoffrey; Nabiryo, Christine; Coutinho, Alex // AIDS Research & Therapy;2008, Vol. 5, Special section p1 

    In a routine service delivery setting in Uganda, we assessed the ability of the WHO clinical stage to accurately identify HIV-infected patients in whom antiretroviral therapy should be started. Among 4302 subjects screened for ART, the sensitivity and specificity (95% CI) of WHO stage III, IV...

  • Predictors of Survival in HIV-Infected Patient after Initiation of HAART in Zewditu Memorial Hospital, Addis Ababa, Ethiopia. Mengesha, Shibre; Belayihun, Bekele; Kumie, Abera // ISRN Otolaryngology;2014, p1 

    Introduction. ART has improved the survival of HIV-infected patients. However, patients in resource-poor countries have higher mortality rates, particularly the first months after initiating ART. In this study we tried to determine the survival factors in HIV-infected patients treated with HAART...

  • HIV Drug Resistance Early Warning Indicators in Namibia with Updated World Health Organization Guidance. Jonas, Anna; Sumbi, Victor; Mwinga, Samson; DeKlerk, Michael; Tjituka, Francina; Penney, Scott; Jordan, Michael R.; Desta, Tiruneh; Tang, Alice M.; Hong, Steven Y. // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Background: In response to concerns about the emergence of HIV drug resistance (HIVDR), the World Health Organization (WHO) has developed a comprehensive set of early warning indicators (EWIs) to monitor HIV drug resistance and good programme practice at antiretroviral therapy (ART) sites....

  • Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study. Winston, Alan; Fätkenheuer, Gerd; Arribas, Jose; Hill, Andrew; van Delft, Yvon; Moecklinghoff, Christiane // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p163 

    Background: Protease inhibitor monotherapy is an attractive treatment option for HIV-infected subjects. Data assessing neuropsychiatric events with the use of protease inhibitor monotherapy are sparse. Methods: Clinician- and patient-reported neuropsychiatric events were assessed over 48 weeks...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics